A Phase 1 interventional study of Lactose-free memantine and Memantine in Healthy, sponsored by H. Lundbeck A/S. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-29.
Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the release of memantine into the bloodstream of two different formulations: one formulation containing lactose and one without lactose.
The study consists of two cohorts: A1 and A2.
Subjects in Cohort A1 will be administered the investigational medicinal product (IMP) in a fasted state and subjects in Cohort A2 will be administered the IMP in a fed state.
Each subject will change cohort during study participation, so that dosing will be done over two periods: either first fed and then fasted, or first fasted and then fed. The two periods will be separated by a period of 28 days (+7 days) where no investigational medicinal product is given.
All subjects will be confined to the clinic from one day prior to dosing until Day 4 (72 hours post-dose) in each dosing period.
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other in- and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
Drug: Lactose-free memantine
(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
Drug: Memantine
Lactose-free memantine tablet, 10 mg; orally as a single dose
Lactose-containing memantine tablet, 10 mg, orally as a single dose
Also known as: Ebixa®
AUC0-72h in fed state for test and reference treatment
Area under the memantine plasma concentration-time curve
Time frame: From zero to 72 hours post dose
AUC0-72h in fasted state for test and reference treatment
Area under the memantine plasma concentration-time curve
Time frame: From zero to 72 hours post dose
Cmax of memantine in fed state for test and reference treatment
Maximum observed plasma concentration of memantine
Time frame: From zero to 72 hours post dose
Cmax of memantine in fasted state for test and reference treatment
Maximum observed plasma concentration of memantine
Time frame: From zero to 72 hours post dose
tmax in fed state for test and reference treatment
Nominal time corresponding to the occurrence of Cmax
Time frame: From zero to 72 hours post dose
tmax in fasted state for test and reference treatment
Nominal time corresponding to the occurrence of Cmax
Time frame: From zero to 72 hours post dose
Ran from Aug 2018 to primary completion in Dec 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine